Lymphoma: MYD88 L265P

PlentiPlex™ MYD88 L265P

For Assisting the Diagnosis of Lymphoma

The PlentiPlex™ MYD88 L265P assay is intended for in vitro diagnosis of the leucine to proline mutation in codon 265 of the Myeloid differentiation primary response 88 protein (MYD88 L265P) in genomic DNA (gDNA) samples. The obtained results of the PlentiPlex™ MYD88 L265P assay are intended for assisting in the discrimination between patients with Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM) and non-Hodgkin lymphoma.

The PlentiPlex™ MYD88 L265P assay combines high sensitivity with ease-of-use and is designed to work on standard real-time PCR equipment. The PlentiPlex™ MYD88 L265P assay is based on PentaBase’s novel and selective INA® technologies including the use of BaseBlockers™ that suppress false positive signals from wild type templates.

Available as ready-to-use and dispense ready

The PlentiPlex™ MYD88 L265P assay is supplied as either “Ready-to-use” or as “Dispense Ready” mixes. Ready-to-use assays are pre-dispensed in PCR strips and require only addition of gDNA for somatic mutation testing. Dispense-ready mixes include oligonucleotides and master mix in separate tubes ready to be dispensed and added gDNA. The technologies are applicable on standard real-time equipment using standard procedures and results can be ready in less than three hours from receiving a sample (including automated DNA extraction).

Key features and benefits of PlentiPlex™ MYD88 L265P

  • Easy and fast: Easy to setup (hands-on-time <2 min/sample) and takes less than three hours from sample to result including DNA extraction.
  • State of the art: Based on PentaBase’s proprietary INA® technology.
  • Open qPCR platform designs: Designed to work on standard real-time PCR instruments.